Trial
NCT00081900
A Safety and Efficacy Study of DENSPM in Patients With Liver Cancer Who Are Not Eligible for Surgical Care
Phase ITERMINATEDOTHER/UNKNOWNConfidence: LOW
Sponsor
Genzyme, a Sanofi Company
Collaborators
—
Condition
Carcinoma, Hepatocellular
Intervention
DENSPM )
Why stopped
This study was terminated early by Genzyme because there were insufficient data to support clinical benefit to HCC patients on the study.
Provenance
Dataset: 2026-07-02 • Source: ClinicalTrials.gov API v2 • Last update: 2015-04-13